Adial Stock Analysis

ADIL
 Stock
  

USD 0.38  0.02  5.00%   

The big decline in price over the last few months for Adial Pharmaceuticals could raise concerns from stakeholders as the firm is trading at a share price of 0.38 on 137,500 in volume. The company management teams failed to add value to investors and position the firm supply of money to exploit market volatility in August. However, diversifying your holdings with Adial Pharmaceuticals or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 8.3. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Adial Pharmaceuticals partners.
Please continue to Trending Equities.
  
The Adial Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Adial Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Adial Stock analysis module also helps to analyze the Adial Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Adial Stock Analysis Notes

About 13.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.52. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adial Pharmaceuticals recorded a loss per share of 0.87. The entity had not issued any dividends in recent years. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Adial Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. For more info on Adial Pharmaceuticals please contact William Stilley at 434 422 9800 or go to https://www.adialpharma.com.

Adial Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Adial Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Adial Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Adial Pharmaceuticals generated a negative expected return over the last 90 days
Adial Pharmaceuticals has high historical volatility and very poor performance
Adial Pharmaceuticals has some characteristics of a very speculative penny stock
Adial Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (17.5 M).
Adial Pharmaceuticals currently holds about 12.69 M in cash with (11.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 13.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Claiborne Cary J of 75000 shares of Adial Pharmaceuticals subject to Rule 16b-3

Adial Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Adial Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adial Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report28th of March 2022
Next Financial Report16th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End28th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Adial Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Adial Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Adial Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Adial Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
14th of September 2022
Financial Statements and Exhibits. Changes in Registrant's Certifying Accountant
View
13th of September 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
6th of September 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
2nd of September 2022
Financial Statements and Exhibits. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
23rd of August 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
16th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
20th of July 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
27th of June 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View

Adial Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Adial Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adial Pharmaceuticals backward and forwards among themselves. Adial Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Adial Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares590.9 K792 K
Blackrock IncCommon Shares224.9 K301 K
Renaissance Technologies LlcCommon Shares169.4 K227 K
Geode Capital Management LlcCommon Shares135.9 K182 K
Susquehanna International Group LlpCommon Shares99.1 K133 K
Css LlcCall Options81.1 K108 K
State Street CorpCommon Shares52.4 K70 K
Millennium Management LlcCommon Shares39.5 K53 K
Note, although Adial Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Adial Market Capitalization

The company currently falls under 'Nano-Cap' category with current market capitalization of 8.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adial Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Adial Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (88.06) % which means that it has lost $88.06 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (214.36) %, meaning that it created substantial loss on money invested by shareholders. Adial Pharmaceuticals management efficiency ratios could be used to measure how well adial pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 26th of September, Adial Pharmaceuticals shows the risk adjusted performance of (0.19), and Mean Deviation of 4.96. Adial Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Adial Pharmaceuticals, which can be compared to its rivals. Please confirm Adial Pharmaceuticals variance, as well as the relationship between the maximum drawdown and semi variance to decide if Adial Pharmaceuticals is priced correctly, providing market reflects its regular price of 0.38 per share. As Adial Pharmaceuticals appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Adial Pharmaceuticals Price Movement Analysis

The output start index for this execution was eight with a total number of output elements of fifty-three. The Moving Average is predictive technique used to analyze Adial Pharmaceuticals price data points by creating a series of averages of different subsets of Adial Pharmaceuticals entire price series.
.

Adial Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adial Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adial Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adial Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Claiborne Cary J few days ago via Macroaxis 
Acquisition by Claiborne Cary J of 75000 shares of Adial Pharmaceuticals subject to Rule 16b-3
William Stilley over a month ago via Macroaxis 
Acquisition by William Stilley of 100000 shares of Adial Pharmaceuticals subject to Rule 16b-3
Claiborne Cary J over a month ago via Macroaxis 
Acquisition by Claiborne Cary J of 1000000 shares of Adial Pharmaceuticals subject to Rule 16b-3
Goodman Tony over two months ago via Macroaxis 
Acquisition by Goodman Tony of 25000 shares of Adial Pharmaceuticals subject to Rule 16b-3
Newman James W Jr over six months ago via Macroaxis 
Acquisition by Newman James W Jr of 40000 shares of Adial Pharmaceuticals subject to Rule 16b-3
Newman James W Jr over six months ago via Macroaxis 
Adial Pharmaceuticals exotic insider transaction detected
Schuyler Kevin over six months ago via Macroaxis 
Bona fide gift to Schuyler Kevin of 90000 shares of Adial Pharmaceuticals subject to Section 16
Claiborne Cary J over six months ago via Macroaxis 
Acquisition by Claiborne Cary J of 130000 shares of Adial Pharmaceuticals subject to Rule 16b-3
William Stilley over six months ago via Macroaxis 
Purchase by William Stilley of 10600 shares of Adial Pharmaceuticals
Newman James W Jr over six months ago via Macroaxis 
Adial Pharmaceuticals exotic insider transaction detected
Claiborne Cary J over six months ago via Macroaxis 
Acquisition by Claiborne Cary J of 60000 shares of Adial Pharmaceuticals subject to Rule 16b-3
Bankole Johnson over six months ago via Macroaxis 
Acquisition or disposition of Adial Pharmaceuticals securities by Bankole Johnson

Adial Pharmaceuticals Predictive Daily Indicators

Adial Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adial Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Adial Pharmaceuticals Forecast Models

Adial Pharmaceuticals time-series forecasting models is one of many Adial Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adial Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Adial Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Adial Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Adial shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Adial Pharmaceuticals. By using and applying Adial Stock analysis, traders can create a robust methodology for identifying Adial entry and exit points for their positions.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Adial Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Current Adial Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Adial analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Adial analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
11.65Strong Buy4Odds
Adial Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Adial analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Adial stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Adial Pharmaceuticals, talking to its executives and customers, or listening to Adial conference calls.
Adial Analyst Advice Details

Adial Stock Analysis Indicators

Adial Pharmaceuticals stock analysis indicators help investors evaluate how Adial Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Adial Pharmaceuticals shares will generate the highest return on investment. By understating and applying Adial Pharmaceuticals stock analysis, traders can identify Adial Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio5.84
Fifty Two Week Low0.4122
Shares Short Prior Month801.23k
Average Daily Volume Last 10 Day336.88k
Average Daily Volume In Three Month753.63k
Shares Percent Shares Out2.67%
Short Percent Of Float2.95%
Forward Price Earnings-0.71
Float Shares18.86M
Fifty Two Week High5.0800
Enterprise Value To Ebitda-0.19
Fifty Day Average0.7460
Two Hundred Day Average1.6356
Please continue to Trending Equities. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for analysis

When running Adial Pharmaceuticals price analysis, check to measure Adial Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adial Pharmaceuticals is operating at the current time. Most of Adial Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Adial Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adial Pharmaceuticals' price. Additionally, you may evaluate how the addition of Adial Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Adial Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Adial Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.